Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures

Journal of Gene Medicine

Volumn 11, Issue 10, 2009, Pages 868-876

  Ansorge, Sven ^a,b   Lanthier, Stéphane ^a   Transfiguracion, Julia ^a   Durocher, Yves ^a   Henry, Olivier ^b   Kamen, Amine ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

Author keywords

Gene therapy; HEK293; Lentiviral vectors; Scalable production; Suspension culture

Indexed keywords

BUTYRIC ACID; DNA; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; POL PROTEIN; POLYETHYLENEIMINE; REV PROTEIN;

ARTICLE; BIOREACTOR; CELL CULTURE; CELL DENSITY; CELL STRAIN HEK293; CELL SUSPENSION; CONTROLLED STUDY; CULTURE MEDIUM; EMBRYO; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VOLUMETRY;

BIOREACTORS; BUTYRATES; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA; GENETIC VECTORS; HUMANS; LENTIVIRUS; TRANSFECTION;

VESICULAR STOMATITIS VIRUS;

EID: 72449162211     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1370     Document Type: Article

References (67)

1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40. (Pubitemid 32095639)
2. Quinonez R, Sutton RE. Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002; 21: 937-951. (Pubitemid 36126697)
3. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotech 2006; 24: 687-696. (Pubitemid 43882120)
4. Kohn DB. Lentiviral vectors ready for prime-time. Nat Biotech 2007; 25: 65-66.
5. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. PNAS 2006; 103: 17372-17377. (Pubitemid 44788976)
6. MacGregor RR. A phase I open label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum Gene Ther 2001; 12: 2028-2029.
7. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267. (Pubitemid 26119138)
8. Warnock JN, Merten OW, Al-Rubeai M. Cell culture processes for the production of viral vectors for gene therapy purposes. Cytotechnology 2006; 50: 141-162. (Pubitemid 44243938)
9. Mitta B, Rimann M, Fussenegger M. Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. Metab Eng 2005; 7: 426-436. (Pubitemid 41790471)
10. Kuroda H, Kutner RH, Bazan NG, Reiser J. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods 2009; 157: 113-121.
11. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004; 122: 131-139. (Pubitemid 39470183)
12. Coleman JE, Huentelman MJ, Kasparov S, et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-228. (Pubitemid 37139701)
13. Lejeune AC, Truran RE, Radcliffe PA, et al. A robust large scale manufacturing process for production of sterile high titre lentiviral vector (ProSavin®) for a phase I/II clinical trial. Twentieth ESACT Meeting, 2007; Dresden, Germany.
14. Bellintani F, Piacenza L, Sciarretta Birolo R, et al. Large scale process for the production and purification of lentiviral vectors for clinical applications. Hum Gene Ther 2008; 19: 1089.
15. Schonely K, Afable C, Slepushkin V, et al. QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. BioProcessing Journal 2003; 2: 39-47.
16. Slepushkin V, Chang N, Cohen R, et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. BioProcessing Journal 2003; 9: 89-95.
17. Cockrell AS, Ma H, Fu K, McCown TJ, Kafri T. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther 2006; 14: 276-284. (Pubitemid 43964495)
18. Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. A packaging cell line for lentivirus vectors. J Virol 1999; 73: 576-584. (Pubitemid 28565401)
19. Klages N, Zufferey R, Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2: 170-176.
20. Ni Y, Sun S, Oparaocha I, et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1- based lentiviral vector. J Gene Med 2005; 7: 818-834. (Pubitemid 40872867)
21. Sparacio S, Pfeiffer T, Schaal H, Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol Ther 2001; 3: 602-612. (Pubitemid 32509855)
22. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005; 5: 387-398. (Pubitemid 41052430)
23. Ikeda Y, Takeuchi Y, Martin F, et al. Continuous high-titer HIV-1 vector production. Nat Biotechnol 2003; 21: 569-572. (Pubitemid 36532025)
24. Throm RE, Ouma A, Zhou S, et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009; 113: 5104-5110.
25. Broussau S, Jabbour N, Mullick A, et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 2008; 16: 500-507. (Pubitemid 351314989)
26. Blesch A. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods 2004; 33: 164-172. (Pubitemid 38569661)
27. Durocher Y, Pham PL, St-Laurent G, et al. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J Virol Methods 2007; 144: 32-40. (Pubitemid 47095034)
28. Hildinger M, Baldi L, Stettler M, Wurm F. High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. Biotechnol Lett 2007; 29: 1713-1721. (Pubitemid 47493534)
29. Segura MM, Garnier A, Durocher Y, Coelho H, Kamen A. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol Bioeng 2007; 98: 789-799. (Pubitemid 350032683)
30. Bartz SR, Rogel ME, Emerman M. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 1996; 70: 2324-2331. (Pubitemid 26087595)
31. Pham PL, Perret S, Doan HC, et al. Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency. Biotechnol Bioeng 2003; 84: 332-344. (Pubitemid 37221535)
32. Pham PL, Perret S, Cass B, et al. Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis. Biotechnol Bioeng 2005; 90: 332-344. (Pubitemid 40779210)
33. Pham P, Kamen A, Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol 2006; 34: 225-237. (Pubitemid 46030396)
34. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30: E9.
35. Karolewski BA, Watson DJ, Parente MK, Wolfe JH. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum Gene Ther 2003; 14: 1287-1296.
36. Dormond E, Meneses-Acosta A, Jacob D, et al. An efficient and scalable process for helper-dependent adenoviral vector production using polyethylenimine-adenofection. Biotechnol Bioeng 2009; 102: 800-810.
37. Derouazi M, Girard P, Van Tilborgh F, et al. Serum-free largescale transient transfection of CHO cells. Biotechnol Bioeng 2004; 87: 537-545. (Pubitemid 39150055)
38. Durocher Y, Pham PL, St-Laurent G, et al. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J Virol Methods 2007; 144: 32-40. (Pubitemid 47095034)
39. Watson DJ, Kobinger GP, Passini MA, Wilson JM, Wolfe JH. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 2002; 5: 528-537.
40. Higashikawa F, Chang L-J. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 2001; 280: 124-131. (Pubitemid 34158058)
41. McTaggart S, Al-Rubeai M. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line. Biotechnol Prog 2000; 16: 859-865. (Pubitemid 30778886)
42. Cruz PE, Goncalves D, Almeida J, Moreira JL, Carrondo MJT. Modeling retrovirus production for gene therapy. 2. Integrated optimization of bioreaction and downstream processing. Biotechnol Prog 2000; 16: 350-357. (Pubitemid 30369003)
43. Cruz PE, Almeida JS, Murphy PN, Moreira JL, Carrondo MJT. Modeling retrovirus production for gene therapy. 1. Determination of optimal bioreaction mode and harvest strategy. Biotechnol Prog 2000; 16: 213-221. (Pubitemid 30228648)
44. Geisse S. Reflections on more than 10 years of TGE approaches. Protein Expr Purif 2009; 64: 99-107.
45. Henry O, Kamen A, Perrier M. Monitoring the physiological state of mammalian cell perfusion processes by on-line estimation of intracellular fluxes. J Process Control 2007; 17: 241-251. (Pubitemid 46210168)
46. Ghani K, Garnier A, Coelho H, et al. Retroviral vector production using suspension-adapted 293GPG cells in a 3 l acoustic filter-based perfusion bioreactor. Biotechnol Bioeng 2006; 95: 653-660. (Pubitemid 44671467)
47. Merten OW. State-of-the-art of the production of retroviral vectors. J Gene Med 2004; 6(Suppl 1): S105-S124.
48. Jaalouk DE, Eliopoulos N, Couture C, Mader S, Galipeau J. Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells. Hum Gene Ther 2000; 11: 1837-1849. (Pubitemid 30676757)
49. Sakoda T, Kasahara N, Hamamori Y, Kedes L. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol 1999; 31: 2037-2047. (Pubitemid 29537603)
50. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
51. Altenburg BC, Via DP, Steiner SH. Modification of the phenotype of murine sarcoma virus-transformed cells by sodium butyrate: effects on morphology and cytoskeletal elements. Exp Cell Res 1976; 102: 223-231.
52. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1981; 42: 65-82.
53. Gloger I, Arad G, Panet A. Regulation of Moloney murine leukemia virus replication in chronically infected cells arrested at the G0/G1 phase. J Virol 1985; 54: 844-850. (Pubitemid 15014718)
54. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133: 2485S-2493S.
55. Gasmi M, Glynn J, Jin M-J, et al. Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol 1999; 73: 1828-1834. (Pubitemid 29098082)
56. Côté J, Garnier A, Massie B, Kamen A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng 1998; 59: 567-575. (Pubitemid 28350457)
57. Pham PL, Perret S, Doan HC, et al. Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency. Biotechnol Bioeng 2003; 84: 332-342. (Pubitemid 37221535)
58. Tom R, Bisson L, Durocher Y. Transient expression in HEK293- EBNA1 cells. In Methods Express: Expression Systems, DysonMR, Durocher Y (eds). Scion Publishing Ltd., Oxfordshire, UK, 2007; 203-223.
59. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471. (Pubitemid 28471781)
60. Jouvenet N, Bieniasz PD, Simon SM. Imaging the biogenesis of individual HIV-1 virions in live cells. Nature 2008; 454: 236-240. (Pubitemid 351969887)
61. Sun X, Hia HC, Goh PE, Yap MGS. High-density transient gene expression in suspension-adapted 293 EBNA1 cells. Biotechnol Bioeng 2008; 99: 108-116.
62. Godbey WT, Mikos AG. Recent progress in gene delivery using non-viral transfer complexes. J Control Release 2001; 72: 115-125.
63. Kunath K, von Harpe A, Fischer D, et al. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release 2003; 89: 113-125. (Pubitemid 36412116)
64. Backliwal G, Hildinger M, Hasija V, Wurm FM. High density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 2008; 99: 721-727. (Pubitemid 351158270)
65. BaldiL, HackerD, AdamM, WurmF. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives Biotechnol Lett 2007; 29: 677-684.
66. Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum Gene Ther 1995; 6: 1195-1202.
67. Jaalouk D, Crosato M, Brodt P, Galipeau J. Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors. Virol J 2006; 3: 27. (Pubitemid 44019884)